SUPN — Supernus, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1625297 ·
Last close
$29.04
Market Cap
$1.69B
52W High
$33.22
52W Low
$21.48
ADV30
3,569,794
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 226,771,000 199,753,000 22,720,000 20,913,000 1,397,690,000 175,884,000 335,212,000
Jun 2026 219,058,000 185,389,000 -3,044,000 -58,371,000 1,428,109,000 179,953,000 396,883,000
Mar 2026 207,705,000 184,314,000 -5,941,000 -2,293,000 1,500,725,000 184,869,000 423,920,000
Dec 2025 211,572,000 188,565,000 13,822,000 -4,105,000 1,452,648,000 128,448,000 390,934,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$19,911,000
Investing CF
$-14,728,000
Financing CF
$31,509,000
CapEx
$-1,338,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$457,212,000
Inventory
$83,924,000
Receivables
$211,656,000
ST Investments
$192,114,000
EBIT TTM
$-119,849,000
Pretax Income TTM
$-123,466,000
Interest Exp TTM
$2,315,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$865,105,984
EBITDA
$116,030,000
Free Cash Flow
$61,711,876
Enterprise Value
$2,117,979,264
Total Cash
$359,459,008
Total Debt
$36,197,000
Shares Out
58,235,716
Trailing EPS
$-0.76
Book Value
$18.24
ROE
-4.2%
ROA
0.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 718,952,000 -36,864,000 -38,550,000 1,452,648,000 390,934,000 1,061,714,000 47,331,000
Dec 2024 661,817,000 75,556,000 73,865,000 1,368,073,000 332,340,000 1,035,733,000 171,951,000
Dec 2023 607,521,000 13,403,000 1,316,000 1,277,673,000 356,157,000 921,516,000 111,085,000
Dec 2022 667,238,000 45,614,000 60,711,000 1,702,508,000 816,304,000 886,204,000 116,826,000

TTM Snapshot

Revenues TTM
$1,331,000,000
NetIncome TTM
$356,000,000
OpCashFlow TTM
—
Assets (Latest)
$1,233,000,000
Forward EPS
$4.17

Max Pain — expiry 2026-12-18

max pain strike: $26.87 · spot: $28.96 · call oi: 2,431 · put oi: 1,683

Peers — same industry

TickerNameMarket CapLastDaily %
BRVE Braveheart Bio, Inc. $1.69B $18.78 —
SDGR Schrodinger, Inc. $1.68B $25.66 —
RARE Ultragenyx Pharmaceutical Inc. $1.70B $16.70 —
STOK Stoke Therapeutics, Inc. $1.73B $26.41 —
ZYME Zymeworks Inc. $1.78B $25.84 —

News headlines (Yahoo Finance, 1h cache)

Does Supernus Pharmaceuticals (SUPN) Still Trade Below Fair Value On Sales?
2026-11-18 01:16 · Yahoo
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
2026-11-10 13:30 · Yahoo
Supernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run Continues
2026-11-10 06:11 · Yahoo
Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued
2026-11-04 14:18 · Yahoo
Supernus Pharmaceuticals (SUPN) Stock May Be Undervalued After ONAPGO Exclusivity
2026-11-03 22:22 · Yahoo
What Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?
2026-11-03 19:15 · Yahoo
Why Indivior Pharmaceuticals Stock Topped the Market Today
2026-11-02 22:03 · Yahoo
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
2026-11-02 14:18 · Yahoo
SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
2026-11-01 01:55 · Yahoo
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative
2026-10-30 22:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.